Fingolimod (Gilenya®)

Zorginstituut Nederland has advised on amending the conditional inclusion of the medicine fingolimod (Gilenya®) in the Medicines Reimbursement System (GVS), whereby they reached the following conclusion.

Based on the criteria of the GVS, the Zorginstituut advises completely removing the condition to fingolimod's inclusion in List 2 and replacing it with another condition.